Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

J.A. Cohen, A.J. Coles, D.L. Arnold, C. Confavreux, E.J. Fox, H.P. Hartung, E. Havrdova, K.W. Selmaj, H.L. Weiner, E. Fisher, V.V. Brinar, G. Giovannoni, M. Stojanovic, B.I. Ertik, St.L. Lake, D.H. Margolin, F. Barkhof, M.A. Panzara, D. Compston

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1819-1828
JournalLancet
Volume380
Issue number9856
DOIs
Publication statusPublished - 2012

Cite this